Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.19 is 20% below its 2-year average of 1.49, around the middle of its 2-year range (0.00–3.20).
As of the fiscal period ended Tuesday, June 30, 2026. 33.26% below its 12-month average of 1.78.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.19.
QUICK RATIO (ACID-TEST)
1.19
QUICK RATIO (ACID-TEST) AVG TTM
1.78
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-33.26%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
-64.53%
vs the sector median at left
Turn Therapeutics Inc.
Market Cap
$346.73M
Quick Ratio (Acid-Test)
1.19
TTM Avg
1.78
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$344.04M
Quick Ratio (Acid-Test)
29.52
TTM Avg
9.54
3Y Avg
9.83
5Y Avg
10.59
Market Cap
$349.70M
Quick Ratio (Acid-Test)
8.24
TTM Avg
5.34
3Y Avg
5.79
5Y Avg
4.44
Market Cap
$353.00M
Quick Ratio (Acid-Test)
1.68
TTM Avg
1.66
3Y Avg
1.70
5Y Avg
1.47
Market Cap
$353.88M
Quick Ratio (Acid-Test)
3.76
TTM Avg
4.71
3Y Avg
6.65
5Y Avg
8.92
Market Cap
$355.36M
Quick Ratio (Acid-Test)
1.02
TTM Avg
1.18
3Y Avg
1.33
5Y Avg
1.63
Market Cap
$355.43M
Quick Ratio (Acid-Test)
24.16
TTM Avg
12.00
3Y Avg
8.65
5Y Avg
7.93
Market Cap
$359.53M
Quick Ratio (Acid-Test)
5.66
TTM Avg
6.21
3Y Avg
5.34
5Y Avg
8.05
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.73M | 1.19 | 1.78 | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | 29.52 | 9.54 | 9.83 | 10.59 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | 8.24 | 5.34 | 5.79 | 4.44 |
| Ocugen, Inc. (OCGN)vs › | $352.67M | 0.80 | 1.96 | 2.47 | 5.28 |
| Embecta Corp. (EMBC)vs › | $353.00M | 1.68 | 1.66 | 1.70 | 1.47 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | 3.76 | 4.71 | 6.65 | 8.92 |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 1.02 | 1.18 | 1.33 | 1.63 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 24.16 | 12.00 | 8.65 | 7.93 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 5.66 | 6.21 | 5.34 | 8.05 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | 12.19 | 4.83 | 10.20 | 8.85 |
Quick Ratio
1.19
Excludes inventory
Current Ratio
1.19
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.19 |
| 2026-03-31 | 2.23 |
| 2025-12-31 | 0.87 |
| 2025-09-30 | 1.43 |
| 2025-06-30 | 3.20 |
| 2024-06-30 | 0.00 |
